Momentum Building: Delcath Systems Spikes on HEPZATO KIT's FDA Nod
- August 15th, 2023
- 333 views
Shares of Delcath Systems, Inc. (Nasdaq: DCTH) surged over 50% following the announcement of FDA approval for HEPZATO KIT (melphalan/Hepatic Delivery System).
This liver-directed therapy is now authorized for adult patients battling metastatic uveal melanoma (mUM), specifically those with unresectable hepatic metastases affecting less than 50% of the liver and limited extrahepatic disease.
This approval addresses a rare and aggressive cancer with high liver involvement, making it a significant advancement in treatment options and the company plans to make the commercial product available in the fourth quarter.
$DCTH was trading at $5.35 in pre-market, reflecting a substantial increase of $2.23 (+71.47%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login